{"protocolSection": {"identificationModule": {"nctId": "NCT01005290", "orgStudyIdInfo": {"id": "P-080646-01"}, "organization": {"fullName": "Ferrer Internacional S.A.", "class": "INDUSTRY"}, "briefTitle": "A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure", "officialTitle": "Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and Ramipril (Cardiovascular Fixed Dose Combination Pill) on Blood Pressure"}, "statusModule": {"statusVerifiedDate": "2012-06", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "primaryCompletionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-22", "studyFirstSubmitQcDate": "2009-10-29", "studyFirstPostDateStruct": {"date": "2009-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-03-30", "resultsFirstSubmitQcDate": "2012-06-20", "resultsFirstPostDateStruct": {"date": "2012-07-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-06-20", "lastUpdatePostDateStruct": {"date": "2012-07-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ferrer Internacional S.A.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the effect on systolic pressure of the 3 drugs given together in the cardiovascular combination pill (acetylsalicylic acid, simvastatin, and ramipril) to the effect on systolic pressure of ramipril given alone."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["cardiovascular", "fixed", "dose", "combination", "pill", "hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Combination pill", "type": "EXPERIMENTAL", "description": "A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.", "interventionNames": ["Drug: Combination pill"]}, {"label": "Ramipril", "type": "ACTIVE_COMPARATOR", "description": "A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.", "interventionNames": ["Drug: Ramipril"]}], "interventions": [{"type": "DRUG", "name": "Combination pill", "description": "A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.", "armGroupLabels": ["Combination pill"]}, {"type": "DRUG", "name": "Ramipril", "description": "A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.", "armGroupLabels": ["Ramipril"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Difference in the Adjusted Mean 24-h Systolic Pressure Results (Using ABPM) Between the Basal and the Final Visit of Each Treatment Period.", "description": "Difference in the adjusted mean 24-h systolic pressure results using ABPM (Ambulatory Blood Pressure Monitoring)in the PP population.", "timeFrame": "Days 7 and 36 of Period 1 and days 49 and 85 of Period 2"}], "secondaryOutcomes": [{"measure": "Difference in the Adjusted Mean 24-h Diastolic Pressure Results Between the Basal and the Final Visit of Each Treatment Period", "description": "Difference in the Adjusted Mean 24-h Diastolic Pressure Results (Using ABPM) Between the Basal and the Final Visit of Each Treatment Period", "timeFrame": "Days 7 and 36 of Period 1 and days 49 and 85 of Period 2"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects will be \u226518 years old\n* Previously untreated systolic pressure result of \u2265120\\<160 mmHg and diastolic pressure result of \u226580\\<100 mmHg\n\nExclusion Criteria:\n\n* Subjects must not have previously received any anti-hypertensive medication\n* must not have a systolic pressure \\<120 mmHg or \u2265160 mmHg and diastolic pressure result of \\<80 mmHg or \u2265100 mmHg\n* must not have had a previous coronary artery bypass graft (CABG)\n* must not have had a previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting stent\n* must not have severe congestive heart failure (New York Heart Classification \\[NYHC\\] III-IV).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Valentin Fuster, MD, PhD", "affiliation": "Icahn School of Medicine at Mount Sinai", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mount Sinai Medical Center", "city": "New York", "state": "New York", "zip": "NY 10029-6574", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "52 subjects enrered the run-in period with ramipril 2.5 mg, 38 subjects were randomized. 20 subjects were randomized to Sequence Combination pill/ Ramipril and 18 subjects to sequence Ramipril /Combination pill.", "recruitmentDetails": "Ninety-four subjects were screened for eligibility, participants met eligibility requirements and entered the run-in period", "groups": [{"id": "FG000", "title": "Pre-randomization Run-In", "description": "Screening period with ramipril 2.5 mg once daily"}, {"id": "FG001", "title": "Combination Pill Then Ramipril", "description": "After randomization, in Period 1 participants received a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks; participants received no intervention during wash-out; in Period 2 participants received a once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks"}, {"id": "FG002", "title": "Ramipril Then Combination Pill", "description": "After randomization, in Period 1 participants received a once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks; participants received no intervention during wash-out; in Period 2 participants received a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks."}], "periods": [{"title": "Run-In", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "52"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Period 1 (5 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "9"}]}]}, {"title": "Washout Period (2 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Period 2 (5 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Randomized Patiens", "description": "All patients who were randomized to both treatment sequences"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.8", "spread": "11.71"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "29"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Difference in the Adjusted Mean 24-h Systolic Pressure Results (Using ABPM) Between the Basal and the Final Visit of Each Treatment Period.", "description": "Difference in the adjusted mean 24-h systolic pressure results using ABPM (Ambulatory Blood Pressure Monitoring)in the PP population.", "populationDescription": "The PP set included all randomized subjects who received at least one dose of IMP, had a baseline primary endpoint measurement, had at least one post baseline primary endpoint measurement, and who had no major protocol deviations. The PP set served as the primary analysis set for analysis of the primary endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Days 7 and 36 of Period 1 and days 49 and 85 of Period 2", "groups": [{"id": "OG000", "title": "Combination Pill", "description": "Difference in the adjusted mean 24-h systolic pressure results (using ABPM) between the basal and the final visit of each treatment period."}, {"id": "OG001", "title": "Ramipril", "description": "Difference in the adjusted mean 24-h diastolic pressure results (using ABPM) between the basal and the final visit of each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.40", "spread": "8.726"}, {"groupId": "OG001", "value": "-4.40", "spread": "8.173"}]}]}]}, {"type": "SECONDARY", "title": "Difference in the Adjusted Mean 24-h Diastolic Pressure Results Between the Basal and the Final Visit of Each Treatment Period", "description": "Difference in the Adjusted Mean 24-h Diastolic Pressure Results (Using ABPM) Between the Basal and the Final Visit of Each Treatment Period", "populationDescription": "The PP set included all randomized subjects who received at least one dose of IMP, had a baseline primary endpoint measurement, had at least one post baseline primary endpoint measurement, and who had no major protocol deviations. The PP set served as the primary analysis set for analysis of the primary endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Days 7 and 36 of Period 1 and days 49 and 85 of Period 2", "groups": [{"id": "OG000", "title": "Combination Pill", "description": "Difference in the adjusted mean 24-h diastolic pressure results (using ABPM) between the basal and the final visit of each treatment period."}, {"id": "OG001", "title": "Ramipril", "description": "Difference in the adjusted mean 24-h diastolic pressure results (using ABPM) between the basal and the final visit of each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.85", "spread": "6.714"}, {"groupId": "OG001", "value": "-2.88", "spread": "5.731"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Participants were followed for the whole study duration, an average of 18 weeks.", "eventGroups": [{"id": "EG000", "title": "Combination Pill", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 3, "otherNumAtRisk": 29}, {"id": "EG001", "title": "Ramipril", "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 1, "otherNumAtRisk": 31}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 29}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 31}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Early termination leading to small numbers of subjects analyzed"}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Communications and publication must be agreed between sponsor and PI"}, "pointOfContact": {"title": "Natalia Oudovenko", "organization": "Ferrer Internacional S.A.", "email": "noudovenko-research@ferrergrupo.com", "phone": "+34 93 509 32 82"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017257", "term": "Ramipril"}], "ancestors": [{"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "relevance": "LOW"}, {"id": "M21713", "name": "Simvastatin", "relevance": "LOW"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}